Twist Bioscience Announces Proposed Public Offering of Common Stock

May 6, 2019 Off By BusinessWire

SAN FRANCISCO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DNA?src=hash" target="_blank"gt;#DNAlt;/agt;–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced that it has commenced an
underwritten public offering of 3,000,000 shares of its common stock. In
addition, the company is expected to grant the underwriters of the
offering an option for a period of 30 days to purchase up to an
aggregate of an additional 450,000 shares of common stock at the public
offering price, less the underwriting discount. The offering is subject
to market and other conditions, and there can be no assurance as to
whether or when the offering may be completed.

Twist intends to use the net proceeds of the offering, along with its
existing cash, cash equivalents and short-term investments to improve
and update its platform and core technologies by investing in equipment,
expanding its NGS research and development capabilities, investing in
production software, consolidating into new operation facilities and
increasing its production capacity. It also intends to use the proceeds
of the offering to expand its commercial operations including marketing,
NGS sales and technical services in the United States, Europe and Asia,
to continue to expand in the pharmaceutical biologics drug discovery and
DNA data storage markets, to establish its NGS operations in China and
for working capital and general corporate purposes.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group
L.L.C. are acting as joint book-running managers for the proposed
offering. Robert W. Baird & Co. Incorporated is acting as lead manager.

A registration statement relating to these securities has been filed
with the Securities and Exchange Commission but has not yet become
effective. These securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes
effective. This offering is being made solely by means of a prospectus.
Copies of the preliminary prospectus related to the offering, when
available, may be obtained from J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, or from Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention:
Prospectus Department, or by telephone at (631) 274-2806, or from
Evercore Group L.L.C. c/o Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, or by telephone at (888)
474-0200, or by email at [email protected].

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, market conditions and the completion of the public
offering on the anticipated terms or at all. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
important factors that may cause Twist Bioscience’s actual results,
performance, or achievements to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, the risks and uncertainties of the ability to attract new
customers and retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive competition
in synthetic biology could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the retention
of a significant customer; risks of third party claims alleging
infringement of patents and proprietary rights or seeking to invalidate
Twist Bioscience’s patents or proprietary rights; and the risk that
Twist Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk factors
set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission on May 2, 2019. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a result
of new information, future events or otherwise.

Contacts

Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
[email protected]

Twist
Media Contact:
Angela Bitting
925-202-6211
[email protected]